Acneiform Eruption Induced by Dacomitinib (PF-00299804) / 대한피부과학회지
Korean Journal of Dermatology
;
: 324-327, 2015.
Article
in Korean
| WPRIM
| ID: wpr-135048
ABSTRACT
Dacomitinib (PF-00299804) is a newly developed irreversible pan-HER (human epidermal growth factor receptor) inhibitor for the treatment of non-small cell lung cancer (NSCLC). Inhibiting HER-1 (epidermal growth factor receptor, EGFR), HER-2, and HER-4 may induce similar cutaneous side effects to those of traditional EGFR inhibitors. We report two patients who developed acneiform eruption on the face and trunk, induced by dacomitinib treatment for NSCLC. The skin lesions appeared 3~4 weeks after the initiation of dacomitinib use, and they improved after oral minocycline and topical clindamycin treatment. There has been no report of acneiform eruption after dacomitinib treatment in Korean dermatology journals.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Skin
/
Clindamycin
/
Acneiform Eruptions
/
Carcinoma, Non-Small-Cell Lung
/
Dermatology
/
Drug Therapy
/
Epidermal Growth Factor
/
Minocycline
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Dermatology
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS